A multicenter, randomized, double blind placebo-controlled trial of amoxicillin/clavulanate for the prophylaxis of fever and infection in neutropenic children with cancer

Pediatric Infectious Disease Journal

Volumn 22, Issue 4, 2003, Pages 359-365

  Castagnola, Elio ^b   Boni, Luca ^b   Giacchino, Mareva ^b   Cesaro, Simone ^b   De Sio, Luigi ^b   Garaventa, Alberto ^b   Zanazzo, Giulio A ^b   Biddau, Pierfrancesco ^b   Rossi, Mario R ^b   Schettini, Francesco ^b   Bruzzi, Paolo ^b   Viscoli, Claudio ^a  

^a UNIVERSITY OF GENOA   (Italy)

^b NONE

Author keywords

Amoxicillin clavulanate; Cancer; Fever; Neutropenia; Pediatrics; Placebo controlled study; Prophylaxis

Indexed keywords

AMOXICILLIN; ANTIFUNGAL AGENT; ANTIVIRUS AGENT; CLAVULANIC ACID; COTRIMOXAZOLE; HEMOPOIETIC GROWTH FACTOR; PLACEBO;

ARTICLE; CANCER; CHILD; CLINICAL ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; FEVER; HUMAN; INCIDENCE; INFECTION CONTROL; LEUKEMIA; LOGISTIC REGRESSION ANALYSIS; LYMPHOMA; MALE; MULTICENTER STUDY; NEUTROPENIA; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SURVIVAL RATE; TREATMENT FAILURE;

EID: 0242499849     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.inf.0000061014.97037.a8     Document Type: Article

References (33)

1. Gruppo Italiano Malattie Ematologiche Maligne dell'Adulto. Prevention of bacterial infection in neutropenic patients with hematologic malignancies: a randomized, multicenter trial comparing norfloxacin with ciprofloxacin: the GIMEMA Infection Program. Ann Intern Med 1991;115:7-12.
2. Reduction of fever and streptococcal bacteremia in granulocytopenic patients with cancer: a trial of oral penicillin V or placebo combined with pefloxacin: International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. JAMA 1994;272:1183-9.
3. Gomez-Martin C, Sola C, Hornedo J, et al. Rifampin does not improve the efficacy of quinolone antibacterial prophylaxis in neutropenic cancer patients: results of a randomized clinical trial. J Clin Oncol 2000;18:2126-34.
4. Viscoli C, Bruzzi P, Glauser M. An approach to the design and implementation of clinical trials of empirical antibiotic therapy in febrile and neutropenic cancer patients. Eur J Cancer 1995;31A:2013-22.
5. Viscoli C, Castagnola E. Planned progressive antimicrobial therapy in neutropenic patients. Br J Haematol 1998;102:879-88.
6. Richard P, Delangle MH, Merrien D, et al. Fluoroquinolone use and fluoroquinolone resistance: is there an association? Clin Infect Dis 1994;19:54-9.
7. Cometta A, Calandra T, Bille J, Glauser MP. Escherichia coli resistant to fluoroquinolones in patients with cancer and neutropenia. N Engl J Med 1994;330:1240-1.
8. Carratala J, Fernandez-Sevilla A, Tubau F, Callis M, Gudiol F. Emergence of quinolone-resistant Escherichia coli bacteremia in neutropenic patients with cancer who have received prophylactic norfloxacin. Clin Infect Dis 1995;20:557-63.
9. Viscoli C, Castagnola E, Giacchino M, et al. Bloodstream infections in children with cancer: a multicentre surveillance study of the Italian Association of Paediatric Haematology and Oncology. Supportive Therapy Group-Infectious Diseases Section. Eur J Cancer 1999;35:770-4.
10. Immunocompromised Host Society. The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient: report of a consensus panel. J Infect Dis 1990;161:397-401.
11. Hughes WT, Pizzo PA, Wade JC, Armstrong D, Webb CD, Young LS. Evaluation of new anti-infective drugs for the treatment of febrile episodes in neutropenic patients: Infectious Diseases Society of America and the Food and Drug Administration. Clin Infect Dis 1992;15(Suppl 1):S206-15.
12. CPMP Working Party on Efficacy of Medicinal Products. EEC note for guidance: good clinical practice for trials on medicinal products in the European Community. Pharmacol Toxicol 1990;67:361-72.
13. Pocock SJ. Allocation of patients to treatment in clinical trials. Biometrics 1979;35:183-97.
14. Garcia Rodriguez LA, Stricker BH, Zimmerman HJ. Risk of acute liver injury associated with the combination of amoxicillin and clavulanic acid. Arch Intern Med 1996;156:1327-32.
15. The International Antimicrobial Therapy Cooperative Group of the European Organization for Research and Treatment of Cancer. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993;119:584-93.
16. Chang HY, Rodriguez V, Narboni G, Bodey GP, Luna MA, Freireich EJ. Causes of death in adults with acute leukemia. Medicine 1976;55:259-68.
17. Feld R, Bodey GP. Infections in patients with malignant lymphoma treated with combination chemotherapy. Cancer 1977;39:1018-25.
18. Gualtieri RJ, Donowitz GR, Kaiser DL, Hess CE, Sande MA. Double-blind randomized study of prophylactic trimethoprim/sulfamethoxazole in granulocytopenic patients with hematologic malignancies. Am J Med 1983;74:934-40.
19. Kramer BS, Carr DJ, Rand KH, et al. Prophylaxis of fever and infection in adult cancer patients: a placebo-controlled trial of oral trimethoprim-sulfamethoxazole plus erythromycin. Cancer 1984;53:329-35.
20. Karp JE, Merz WG, Hendricksen C, et al. Oral norfloxacin for prevention of Gram-negative bacterial infections in patients with acute leukemia and granulocytopenia: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1987;106:1-7.
21. Trimethoprim-sulfamethoxazole in the prevention of infection in neutropenic patients. EORTC International Antimicrobial Therapy Project Group. J Infect Dis 1984;150:372-9.
22. Casali A, Verri C, Paoletti G, et al. Chemoprophylaxis of bacterial infections in granulocytopenic cancer patients using norfloxacin. Chemioterapia 1988;7:327-9.
23. Winston DJ, Ho WG, Champlin RE, et al. Norfloxacin for prevention of bacterial infections in granulocytopenic patients. Am J Med 1987;82:40-6.
24. Pignon B, Thiriet L, Aubert D, et al. Evaluation of the efficacy of prophylactic intravenous antibiotherapy with ceftriaxone in post-chemotherapy agranulocytic patients. Nouv Rev Fr Hematol 1990;32:249-52.
25. Talbot GH, Cassileth PA, Paradiso L, Correa-Coronas R, Bond L. Oral enoxacin for infection prevention in adults with acute nonlymphocytic leukemia: The Enoxacin Prophylaxis Study Group. Antimicrob Agents Chemother 1993;37:474-82.
26. Lew MA, Kehoe K, Ritz J, et al. Prophylaxis of bacterial infections with ciprofloxacin in patients undergoing bone marrow transplantation. Transplantation 1991;51:630-6.
27. Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol 1998;16:1179-87.
28. Cruciani M, Rampazzo R, Malena M, et al. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 1996;23:795-805.
29. Castagnola E, Viscoli C. Gram-positive infections and quinolones in neutropenia. Ann Intern Med 1997;126:830-1.
30. Cometta A, Kern WV, Debock R, et al. Double-blind trial of vancomycin (Van) versus placebo (Pla) for persistent fever in neutropenic cancer patients (NCP) given piperacillin/tazobactam (PT) monotherapy [Abstract L-774]. In: 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, December, 2001. Washington, DC: American Society for Microbiology, 2001.
31. Murphy M, Brown AE, Sepkowitz KA, Bernard EM, Kiehn TE, Armstrong D. Fluoroquinolone prophylaxis for the prevention of bacterial infections in patients with cancer: is it justified? Clin Infect Dis 1997;25:346-8.
32. Harbarth S, Harris AD, Carmeli Y, Samore MH. Parallel analysis of individual and aggregated data on antibiotic exposure and resistance in Gram-negative bacilli. Clin Infect Dis 2001;33:1462-8.
33. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med 1996;335:1445-53.